Related Experiment Video
Updated: Sep 17, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Probiotic-Enhanced Porous Bio-Hybrids with Inflammatory Targeting, ROS Scavenging, and Long-Term Drug Release for
Luna Quan1, Yang Ouyang2, Weiwen Liang2
1PCFM Lab, School of Chemistry, Sun Yat-sen University, Guangzhou, 510006, P. R. China.
None:
Functional porous materials hold significant promise for biomedical applications owing to their high surface area and customizable pore architectures. However, the complex gastrointestinal environment poses considerable challenges for conventional nanomaterials in achieving targeted accumulation and controlled drug release. Herein, a kind of novel probiotic-enhanced porous bio-hybrids (E-xPAM@ASA) is designed via bio-hybridization of 5-aminosalicylic acid-loaded hairy microporous nanospheres (xPAM@ASA) with probiotic Escherichia coli Nissle 1917. Benefiting from the intrinsic inflammatory-targeting capability of EcN, the E-xPAM@ASA can accumulate in the inflammatory sites of the intestine. The unique porous architecture of xPAM@ASA not only facilitates high drug loading and long-term release but also provides abundant adsorption sites for effective reactive oxygen species scavenging. In a dextran sulfate sodium-induced ulcerative colitis murine model, E-xPAM@ASA demonstrate superior therapeutic outcomes, including mucosal repair, inflammation alleviation, and microbiota regulation. These findings highlight the potential of the multifunctional nanocomposite as a precise therapeutic platform for the treatment of intestinal inflammation.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Constipation-Predominant IBS